Acceleron Pharma, Inc.;Ludwig Institute for Cancer Research Ltd.
发明人:
Grinberg, Asya,Seehra, Jasbir,Pearsall, Robert Scott,Pietras, Kristian,Kumar, Ravindra,Knopf, John
申请号:
AU2016200018
公开号:
AU2016200018A1
申请日:
2016.01.04
申请国别(地区):
AU
年份:
2016
代理人:
摘要:
#$%^&*AU2016200018A120160128.pdf#####ABSTRACT In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALKl) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis -related disorders. Additionally, the disclosure demonstrates that inhibitors of ALKI may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALKI and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction7/18 0-J-